Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Dianthus Therapeutics, Inc. /DE/ (DNTH)

$79.33 +3.32% NASDAQ: DNTH · 15-min delayed
  • NEW YORK, New York
  • Public · NASDAQ: DNTH
  • 92 employees
$5.7BMarket cap
$2.0MRevenue · FY2025
-$162.3MNet income
92Employees
DNTHNASDAQ
2023IPO

About Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2025
$2.0M
Net income
-$162.3M
Total assets
$530.9M
Market cap
$5.7B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: DNTH
$79.33 +3.32%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$32.92 $115.96

52-week range

Market cap
$5.7B
Shares outstanding
71.6M
Open
—
Day range
–
Prev close
—
Volume
—
IPO date
Sep 12, 2023

Dianthus Therapeutics, Inc. /DE/ (DNTH) Stock Price

  • Reported a net loss of $162.3M in FY2025.
  • Trading 32% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Dianthus Therapeutics, Inc. /DE/.

Write a review
Newsroom

News about Dianthus Therapeutics, Inc. /DE/

News & sentiment via Polygon.io

FAQ

Dianthus Therapeutics, Inc. /DE/: frequently asked questions

Is Dianthus Therapeutics, Inc. /DE/ an American company?

Dianthus Therapeutics, Inc. /DE/ is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Dianthus Therapeutics, Inc. /DE/ headquartered?

Dianthus Therapeutics, Inc. /DE/ is headquartered in New York, New York, United States.

Is Dianthus Therapeutics, Inc. /DE/ publicly traded?

Yes — Dianthus Therapeutics, Inc. /DE/ is a publicly traded company. Its stock trades under the ticker symbol DNTH on the NASDAQ.

What does Dianthus Therapeutics, Inc. /DE/ do?

Dianthus Therapeutics, Inc. /DE/ is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →